If you or someone you love lives with sickle cell disease (SCD), you already know the drill: pain crises that show up without warning, hospital visits, and a lifetime of managing a condition that used to have very few real treatment options. For decades, the main tools were pain management, blood transfusions, and — for a lucky few with a matched donor — a bone marrow transplant.
That picture has changed dramatically. In the last couple of years, the first gene therapies for sickle cell disease reached patients, and a new wave of treatments is right behind them. This guide breaks down what's actually new, what's proven, and what's still experimental — in plain English.
A Quick Refresher: What Is Sickle Cell Disease?
Sickle cell disease is an inherited blood disorder caused by a mutation in the gene that makes hemoglobin, the protein in red blood cells that carries oxygen. That mutation makes red blood cells stiff and curved (sickle-shaped) instead of round and flexible. Sickled cells get stuck in blood vessels, blocking blood flow and causing intensely painful episodes called vaso-occlusive crises, along with long-term damage to organs like the kidneys, lungs, and brain. You can read a plain-language overview from the CDC's sickle cell disease page and more clinical detail from the NHLBI.
The Big Breakthrough: Gene Therapy Finally Arrives
For the first time, there are treatments designed to fix the root cause of sickle cell disease rather than just manage its symptoms.
Casgevy (exagamglogene autotemcel) uses CRISPR gene-editing technology — the same Nobel Prize–winning tool that lets scientists edit DNA with precision — to switch a patient's own stem cells back into producing fetal hemoglobin, a form of hemoglobin that doesn't sickle. Lyfgenia (lovotibeglogene autotemcel) takes a different route, using a modified virus to add a working copy of a hemoglobin gene. Both were approved by the FDA in December 2023 — a genuinely historic moment, since it marked the first cell-based gene therapies approved for sickle cell disease.
Since then, the approval has expanded. The FDA has broadened Casgevy's use to children as young as 2 years old, making it the first gene therapy of its kind available to such young patients with either sickle cell disease or transfusion-dependent beta-thalassemia.
It's worth being honest about the process, though: these therapies are not a simple pill or injection. Patients have their own stem cells collected, sent to a lab for editing, and then undergo chemotherapy to prepare their bone marrow before the edited cells are infused back in. It's a demanding, months-long process, and access remains limited — the treatment is expensive, and only a small number of specialized hospital centers currently offer it. In England, NICE approved NHS access to Casgevy for certain patients with severe disease starting in early 2025, but it's expected to help only around 50 people a year there, out of many thousands living with the condition.
What's Coming Next: Simpler, Broader Gene-Based Approaches
Researchers know that a treatment requiring chemotherapy and a specialized hospital stay will never reach most of the roughly 100,000 people living with sickle cell disease in the U.S. alone, let alone the millions affected worldwide. So the next generation of therapies is aiming for something easier to deliver.
Base editing, a more precise cousin of CRISPR that changes a single DNA letter instead of cutting the DNA strand, is being developed by Beam Therapeutics. Its candidate, known as risto-cel, has shown encouraging early results, and the company has said it may file for FDA approval as soon as late 2026, according to recent coverage from Labiotech.
In vivo gene editing — meaning the gene editing happens directly inside the patient's body, without removing and re-infusing stem cells — is the goal of several biotech companies, including Ensoma. If this approach works, it could remove the need for stem cell collection and chemotherapy altogether, dramatically simplifying treatment.
None of these newer approaches are approved yet, and they're still working through clinical trials, but they represent a real effort to make a potential cure more accessible rather than reserved for a small group of patients who can get to a major medical center.
A Cautionary Update: Not Every "New" Treatment Panned Out
It's important to give a balanced picture, because not every recent development has been positive. Voxelotor (Oxbryta), a once-daily pill approved in 2019 to help reduce red blood cell sickling, was voluntarily withdrawn from the global market by Pfizer in September 2024. According to the FDA's safety alert, new clinical data showed the drug's risks — including more frequent pain crises and deaths in some patients — outweighed its benefits. If you or a family member were taking Oxbryta, the FDA recommends talking to your care team promptly about switching to an alternative.
This is a good reminder that "newest" doesn't automatically mean "best," and it's always worth discussing any treatment change with a hematologist who specializes in sickle cell care.
What's Actually Available and Working Today
Alongside the gene therapy headlines, several established treatments remain the backbone of sickle cell care for most patients:
Hydroxyurea, a decades-old medication that boosts fetal hemoglobin and reduces pain crises, remains a first-line, well-studied option.
Crizanlizumab (Adakveo), an infused medication that helps prevent blood cells from sticking together and blocking vessels.
L-glutamine (Endari), an oral therapy that can reduce the frequency of pain crises.
Bone marrow (stem cell) transplant from a matched donor remains the longest-standing potential cure, though it's limited by the difficulty of finding a suitable donor — fewer than 20% of patients have a matched sibling, according to the California Institute for Regenerative Medicine.
Why This Moment Matters
Sickle cell disease has historically been underfunded relative to its impact, and patients — particularly in lower-income countries — have long faced major gaps in care. The arrival of real gene therapies, even with all their current limitations, is a signal that the science has turned a corner. Researchers Stuart Orkin and Swee Lay Thein were even awarded a 2026 Breakthrough Prize for foundational work explaining how switching on fetal hemoglobin could treat the disease — work that underpins virtually all of today's gene therapies.
The next few years will likely be about closing the access gap: making these treatments simpler, safer, and affordable enough to reach the people who need them most, not just those near a handful of specialized centers.
Talk to Your Care Team
If you have sickle cell disease or care for someone who does, the most useful next step is a conversation with a hematologist familiar with the current treatment landscape — the field is moving quickly, and eligibility for gene therapy or clinical trials depends on individual health history. Organizations like the Sickle Cell Disease Association of America can help connect patients with specialized centers and up-to-date resources.
This article is for general information only and isn't medical advice. Please speak with a qualified healthcare provider about your specific situation.